Skip to main content
PEPTARA LABS
Get Started

Tirzepatide For Weight Loss

Tirzepatide for Weight Loss: What the SURMOUNT Trials Found

Published by · Updated · How we research and check our pages

The short answer

Tirzepatide for weight loss was tested in the SURMOUNT trials, and this page from Peptara Labs (peptaralabs.io) reports what they found: in SURMOUNT-1, adults without diabetes in the highest dose group lost about 20.9 percent of body weight over 72 weeks in the primary analysis, and about 22.5 percent in the analysis that assumed full adherence (Jastreboff et al., 2022). It is a dual agonist: one molecule turns on both the GIP and the GLP-1 receptor, unlike single GLP-1 drugs. For scale, semaglutide produced about 14.9 percent mean weight loss in STEP 1 (Wilding et al., 2021), and a head-to-head diabetes trial, SURPASS-2, favored tirzepatide (Frias et al., 2021). Weight loss tends to slow over time (Horn et al., 2025), and much of it returned after treatment stopped (Aronne et al., 2024).

This page is general educational information, research-use framing only, not medical advice. Research-grade tirzepatide is not approved for human use.

What does tirzepatide do for weight loss?

Tirzepatide is a dual-agonist peptide that turns on two gut-hormone receptors at once, and in trials this dual action produced larger average weight loss than older single-receptor drugs (Jastreboff et al., 2022).

It is a single molecule that acts on both the GIP receptor and the GLP-1 receptor. These are the receptors for two natural "incretin" hormones the gut releases after eating. By acting on both, tirzepatide lowers appetite and changes how the body handles food and blood sugar. The main weight-loss trial, SURMOUNT-1, tested this in adults with obesity or with overweight plus a weight-related condition, without diabetes (Jastreboff et al., 2022). Tirzepatide is approved for chronic weight management under the brand Zepbound and for type 2 diabetes under the brand Mounjaro (FDA, 2023). Beyond the brand products, tirzepatide also circulated as compounded and research-grade material; see how those categories differ in our guide to compounded tirzepatide.

How does tirzepatide work in the body? (GIP plus GLP-1)

Tirzepatide is a dual GIP and GLP-1 receptor agonist, which means one molecule activates two incretin pathways that reduce appetite and slow how fast the stomach empties (Jastreboff et al., 2022).

The GLP-1 pathway is the same one used by semaglutide (Wilding et al., 2021). It lowers hunger signals and slows gastric emptying. Tirzepatide adds the GIP pathway on top of that. The combination of both receptors is what sets tirzepatide apart from GLP-1-only drugs.

How much weight did people lose in the tirzepatide trials?

In SURMOUNT-1, participants in the highest dose group lost about 20.9 percent of their body weight over 72 weeks in the primary analysis, and about 22.5 percent in the analysis that assumed full adherence (Jastreboff et al., 2022).

SURMOUNT-1 ran for 72 weeks and reported that weight loss rose across its dose groups (Jastreboff et al., 2022). The trial reported two analyses. The treatment-regimen estimand counts everyone from randomization, including people who stopped the drug, and gave the more conservative numbers. The efficacy estimand estimates the effect with full adherence to treatment, and gave the higher numbers, including the widely quoted 22.5 percent for the highest dose group.

Weight change by dose group in SURMOUNT-1

GroupMean weight change (primary, treatment-regimen)Mean weight change (efficacy estimand)Source
Lowest dose groupabout -15.0 percentabout -16.0 percentJastreboff et al., 2022
Middle dose groupabout -19.5 percentabout -21.4 percentJastreboff et al., 2022
Highest dose groupabout -20.9 percentabout -22.5 percentJastreboff et al., 2022
Placeboabout -3.1 percentabout -2.4 percentJastreboff et al., 2022

How does tirzepatide compare to semaglutide?

Reported weight loss was larger for tirzepatide, and a head-to-head diabetes trial favored it, though the main weight-loss results come from separate trials (Frias et al., 2021; Jastreboff et al., 2022; Wilding et al., 2021).

SURPASS-2 compared tirzepatide against semaglutide in adults with type 2 diabetes and reported greater reductions in both blood sugar and body weight with tirzepatide (Frias et al., 2021). For weight specifically, tirzepatide's SURMOUNT-1 result (about 20.9 percent in the highest dose group, primary analysis) was higher than semaglutide's STEP 1 result (about 14.9 percent), but these were different trials with different participants (Jastreboff et al., 2022; Wilding et al., 2021). A later head-to-head obesity trial, SURMOUNT-5, also reported greater weight loss with tirzepatide than semaglutide (Aronne et al., 2025).

FeatureTirzepatideSemaglutide
Receptor targetsGIP and GLP-1 (Jastreboff et al., 2022)GLP-1 only (Wilding et al., 2021)
Key weight-loss trialSURMOUNT-1STEP 1
Reported weight lossabout 20.9 percent, primary (Jastreboff et al., 2022)about 14.9 percent (Wilding et al., 2021)
Head-to-head dataSURPASS-2 favored tirzepatide in type 2 diabetes (Frias et al., 2021)SURPASS-2 comparator (Frias et al., 2021)

For a fuller side-by-side, see semaglutide vs tirzepatide.

How durable was tirzepatide weight loss in trials?

Average losses in trials were large, but results varied widely across participants, weight loss slowed over time, and a large share returned after treatment stopped (Horn et al., 2025; Aronne et al., 2024).

The trial figures are averages. Some participants lost much more, some much less. Weight loss on tirzepatide also tends to reach a plateau after a period of treatment. A post-hoc analysis of SURMOUNT-1 and SURMOUNT-4 reported that most participants had reached a weight plateau by around week 72 (Horn et al., 2025). Part of the difficulty in going further is adaptive thermogenesis, where the body lowers its energy use after weight loss and works against further loss (Rosenbaum and Leibel, 2010). And in SURMOUNT-4, people who stopped tirzepatide regained much of their lost weight, while those who continued kept it off (Aronne et al., 2024). The same pattern shows up with semaglutide, where about two-thirds of lost weight returned within a year of stopping (Wilding et al., 2022).

What did trials report about side effects?

The most commonly reported effects in tirzepatide trials were gastrointestinal, such as nausea, diarrhea, and constipation, mostly mild to moderate and most common early in treatment (Jastreboff et al., 2022).

In SURMOUNT-1, these gastrointestinal events were the most common reason participants reduced or stopped treatment (Jastreboff et al., 2022).

Tirzepatide For Weight Loss: FAQ

How much weight did participants lose in SURMOUNT-1?

In SURMOUNT-1, the highest dose group lost about 20.9 percent of body weight over 72 weeks in the primary analysis, and about 22.5 percent in the analysis assuming full adherence (Jastreboff et al., 2022).

Is tirzepatide better than semaglutide for weight loss?

Reported weight loss was larger for tirzepatide, SURPASS-2 favored it in adults with type 2 diabetes (Frias et al., 2021), and the head-to-head SURMOUNT-5 obesity trial also favored it (Aronne et al., 2025), though the main single-drug weight-loss trials were run separately (Jastreboff et al., 2022; Wilding et al., 2021).

Does weight come back after tirzepatide is stopped?

Often, yes. SURMOUNT-4 reported substantial regain after tirzepatide was stopped (Aronne et al., 2024), and semaglutide data showed about two-thirds of lost weight returned within a year (Wilding et al., 2022).

How does tirzepatide cause weight loss?

It activates two incretin receptors, GIP and GLP-1, which lower appetite and slow gastric emptying (Jastreboff et al., 2022).

Why does weight loss slow down over time?

The body adapts by lowering energy use after weight loss (Rosenbaum and Leibel, 2010), and a post-hoc analysis of the SURMOUNT trials found most participants reached a plateau by about week 72 (Horn et al., 2025).

References

  1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
  2. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183. PMID 33567185.
  3. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647.
  4. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945. PMID 38078870.
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. doi:10.1056/NEJMoa2416394.
  6. Horn DB, et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. PMC12096058.
  7. Wilding JPH, Batterham RL, Davies MJ, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725. PMC9542252.
  8. Rosenbaum M, Leibel RL. Adaptive thermogenesis in humans. Int J Obes (Lond). 2010;34(Suppl 1):S47-S55. doi:10.1038/ijo.2010.184. PMC3673773.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, not medical advice. Research-grade material is not for human use.

Chat with us